Drug intelligence / Profile preview

18F-LNC1017

Development stage: Preclinical
Lead developer: Yantai Lannacheng Biotechnology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-LNC1017 is a diagnostic radiopharmaceutical developed by LNC Pharma. It is an 18F-labeled positron emission tomography (PET) tracer designed to target the cholecystokinin B receptor (CCK2R), which is overexpressed in several neuroendocrine and epithelial tumors. The agent is primarily being developed for the visualization and staging of small cell lung cancer (SCLC) and medullary thyroid cancer (MTC). By binding specifically to CCK2R, 18F-LNC1017 allows for high-contrast PET imaging to detect primary tumors and metastatic lesions.

Targets

CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on 18F-LNC1017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-LNC1017.

Explore the full profile